By Jason Derry —

Sigma-Aldrich Co. has announced a licensing deal with NeuroSurvival Technologies Ltd. by which Sigma-Aldrich will be allowed to market and manufacture a marker that can detect apoptosis in vitro and in vivo.  The marker, commercially known as Apo-TRACE, is one of a number of small molecules, referred to collectively as ApoSense™, that NeuroSurvival has developed to detect apoptotic cells in vivo.  An overview of NeuroSurvival’s ApoSense™ technology is available here.  The markers can be used for molecular imaging in the areas of disease staging/diagnosis, treatment monitoring, and drug development.

ApoSense™  Positron Emission Tomography (PET) scans can be viewed here.

Jason Derry, Ph.D., who graduated with honors from DePaul University
College of Law, is a molecular biologist and founding author of Patent Docs.